These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - Roles of Rap1 geranylgeranylation and mitochondrial dysfunction. Sanvee GM; Hitzfeld L; Bouitbir J; Krähenbühl S Biochem Pharmacol; 2021 Oct; 192():114750. PubMed ID: 34461118 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Mullen PJ; Zahno A; Lindinger P; Maseneni S; Felser A; Krähenbühl S; Brecht K Biochim Biophys Acta; 2011 Dec; 1813(12):2079-87. PubMed ID: 21839782 [TBL] [Abstract][Full Text] [Related]
7. Imoxin inhibits tunicamycin-induced endoplasmic reticulum stress and restores insulin signaling in C2C12 myotubes. Eo H; Valentine RJ Am J Physiol Cell Physiol; 2021 Aug; 321(2):C221-C229. PubMed ID: 34077277 [TBL] [Abstract][Full Text] [Related]
8. Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation. Yaluri N; Modi S; Kokkola T Biochem Biophys Res Commun; 2016 Nov; 480(2):194-200. PubMed ID: 27743890 [TBL] [Abstract][Full Text] [Related]
9. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. Tong JF; Yan X; Zhu MJ; Du M J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604 [TBL] [Abstract][Full Text] [Related]
10. The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity. Bonifacio A; Sanvee GM; Bouitbir J; Krähenbühl S Biochim Biophys Acta; 2015 Aug; 1853(8):1841-9. PubMed ID: 25913013 [TBL] [Abstract][Full Text] [Related]
11. C2C12 myoblasts are more sensitive to the toxic effects of simvastatin than myotubes and show impaired proliferation and myotube formation. Sanvee GM; Bouitbir J; Krähenbühl S Biochem Pharmacol; 2021 Aug; 190():114649. PubMed ID: 34111424 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Bonifacio A; Mullen PJ; Mityko IS; Navegantes LC; Bouitbir J; Krähenbühl S Arch Toxicol; 2016 Jan; 90(1):203-15. PubMed ID: 25300705 [TBL] [Abstract][Full Text] [Related]
13. Insulin down-regulates the expression of ubiquitin E3 ligases partially by inhibiting the activity and expression of AMP-activated protein kinase in L6 myotubes. Deng HP; Chai JK; Shen CA; Zhang XB; Ma L; Sun TJ; Hu QG; Chi YF; Dong N Biosci Rep; 2015 Jul; 35(4):. PubMed ID: 26193886 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes. Li W; Liang X; Zeng Z; Yu K; Zhan S; Su Q; Yan Y; Mansai H; Qiao W; Yang Q; Qi Z; Huang Z Biomed Pharmacother; 2016 Oct; 83():194-200. PubMed ID: 27470565 [TBL] [Abstract][Full Text] [Related]
15. A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle. Lai YC; Liu Y; Jacobs R; Rider MH Biochem J; 2012 Oct; 447(1):137-47. PubMed ID: 22793019 [TBL] [Abstract][Full Text] [Related]
16. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Castillero E; Alamdari N; Lecker SH; Hasselgren PO Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3β is required for the induction of skeletal muscle atrophy. Verhees KJ; Schols AM; Kelders MC; Op den Kamp CM; van der Velden JL; Langen RC Am J Physiol Cell Physiol; 2011 Nov; 301(5):C995-C1007. PubMed ID: 21832246 [TBL] [Abstract][Full Text] [Related]
20. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. Sacher J; Weigl L; Werner M; Szegedi C; Hohenegger M J Pharmacol Exp Ther; 2005 Sep; 314(3):1032-41. PubMed ID: 15914674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]